Loza Elena, Morosini María Isabel, Pascual Alvaro, Tubau Fe, Alcalá Juan, Liñares Josefina, Hernández-Bello José Ramón, Baquero Fernando, Perea Evelio, Martín Rogelio, Jones Ronald N, Cantón Rafael
Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Madrid, España.
Enferm Infecc Microbiol Clin. 2008 Oct;26(8):489-94.
Daptomycin is a bactericidal lipopeptide antibiotic, active against gram-positive bacteria. In this study, the comparative in vitro activity of daptomycin and other antimicrobial agents against isolates recovered in 3 Spanish hospitals from 2002 to 2006 was determined as part of the international SENTRY antimicrobial resistance surveillance program. The possible therapeutic role of daptomycin is addressed in the light of Spanish susceptibility data.
Antimicrobial susceptibility testing was performed by the microdilution method with 1398 consecutively recovered gram-positive isolates.
All the staphylococci (n = 1024), enterococci (n = 228), and streptococci (n = 146) studied were susceptible to daptomycin. The highest MIC values were 1, 4, and 0.5 microg/mL, respectively, regardless of methicillin, vancomycin, or penicillin resistance status. All Staphylococcus aureus isolates were also susceptible to vancomycin, teicoplanin, linezolid, and quinupristin-dalfopristin. Coagulase-negative staphylococci were susceptible to vancomycin, linezolid, and quinupristin-dalfopristin. Only daptomycin and linezolid were active against all enterococcal isolates. In addition, vancomycin, teicoplanin, and ampicillin were fully active against Enterococcus faecalis. Daptomycin, vancomycin, teicoplanin, linezolid, and quinupristin-dalfopristin were active against all Streptococcus pyogenes, S. agalactiae, and S. viridans group isolates. The distribution of daptomycin MIC values in S. aureus and enterococci was homogeneously sustained along the 5-year study period.
The sustained antimicrobial activity of daptomycin against staphylococci, enterococci, and streptococci in Spain makes this antibiotic an excellent therapeutic option in severe infection caused by gram-positive microorganisms, including those with multiresistance.
达托霉素是一种杀菌性脂肽类抗生素,对革兰氏阳性菌具有活性。在本研究中,作为国际哨兵抗菌药物耐药性监测项目的一部分,测定了2002年至2006年期间从3家西班牙医院分离出的菌株中达托霉素与其他抗菌药物的体外比较活性。根据西班牙的药敏数据探讨了达托霉素可能的治疗作用。
采用微量稀释法对1398株连续分离出的革兰氏阳性菌进行药敏试验。
所研究的所有葡萄球菌(n = 1024)、肠球菌(n = 228)和链球菌(n = 146)对达托霉素敏感。无论甲氧西林、万古霉素或青霉素耐药状态如何,最高MIC值分别为1、4和0.5μg/mL。所有金黄色葡萄球菌分离株也对万古霉素、替考拉宁、利奈唑胺和奎奴普丁-达福普汀敏感。凝固酶阴性葡萄球菌对万古霉素、利奈唑胺和奎奴普丁-达福普汀敏感。只有达托霉素和利奈唑胺对所有肠球菌分离株有活性。此外,万古霉素、替考拉宁和氨苄西林对粪肠球菌完全有活性。达托霉素、万古霉素、替考拉宁、利奈唑胺和奎奴普丁-达福普汀对所有化脓性链球菌、无乳链球菌和草绿色链球菌群分离株有活性。在为期5年的研究期间,金黄色葡萄球菌和肠球菌中达托霉素MIC值的分布呈均匀持续状态。
达托霉素在西班牙对葡萄球菌、肠球菌和链球菌具有持续的抗菌活性,使其成为治疗革兰氏阳性微生物引起的严重感染(包括多重耐药菌感染)的极佳治疗选择。